Skip to main content
Top
Published in: Cost Effectiveness and Resource Allocation 1/2006

Open Access 01-12-2006 | Methodology

Can discrete event simulation be of use in modelling major depression?

Authors: Agathe Le Lay, Nicolas Despiegel, Clément François, Gérard Duru

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2006

Login to get access

Abstract

Background

Depression is among the major contributors to worldwide disease burden and adequate modelling requires a framework designed to depict real world disease progression as well as its economic implications as closely as possible.

Objectives

In light of the specific characteristics associated with depression (multiple episodes at varying intervals, impact of disease history on course of illness, sociodemographic factors), our aim was to clarify to what extent "Discrete Event Simulation" (DES) models provide methodological benefits in depicting disease evolution.

Methods

We conducted a comprehensive review of published Markov models in depression and identified potential limits to their methodology. A model based on DES principles was developed to investigate the benefits and drawbacks of this simulation method compared with Markov modelling techniques.

Results

The major drawback to Markov models is that they may not be suitable to tracking patients' disease history properly, unless the analyst defines multiple health states, which may lead to intractable situations. They are also too rigid to take into consideration multiple patient-specific sociodemographic characteristics in a single model. To do so would also require defining multiple health states which would render the analysis entirely too complex. We show that DES resolve these weaknesses and that its flexibility allow patients with differing attributes to move from one event to another in sequential order while simultaneously taking into account important risk factors such as age, gender, disease history and patients attitude towards treatment, together with any disease-related events (adverse events, suicide attempt etc.).

Conclusion

DES modelling appears to be an accurate, flexible and comprehensive means of depicting disease progression compared with conventional simulation methodologies. Its use in analysing recurrent and chronic diseases appears particularly useful compared with Markov processes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Paykel ES, Brugha T, Fryers T: Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 2005,15(4):411–423. 10.1016/j.euroneuro.2005.04.008PubMedCrossRef Paykel ES, Brugha T, Fryers T: Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 2005,15(4):411–423. 10.1016/j.euroneuro.2005.04.008PubMedCrossRef
2.
go back to reference Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997,349(9064):1498–1504. 10.1016/S0140-6736(96)07492-2PubMedCrossRef Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997,349(9064):1498–1504. 10.1016/S0140-6736(96)07492-2PubMedCrossRef
3.
go back to reference Segal ZV, Pearson JL, Thase ME: Challenges in preventing relapse in major depression. Report of a National Institute of Mental Health Workshop on state of the science of relapse prevention in major depression. J Affect Disord 2003,77(2):97–108. 10.1016/S0165-0327(02)00112-XPubMedCrossRef Segal ZV, Pearson JL, Thase ME: Challenges in preventing relapse in major depression. Report of a National Institute of Mental Health Workshop on state of the science of relapse prevention in major depression. J Affect Disord 2003,77(2):97–108. 10.1016/S0165-0327(02)00112-XPubMedCrossRef
4.
go back to reference Drummond M, Jonsson B, Rutten F: The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997,40(3):199–215. 10.1016/S0168-8510(97)00901-9PubMedCrossRef Drummond M, Jonsson B, Rutten F: The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 1997,40(3):199–215. 10.1016/S0168-8510(97)00901-9PubMedCrossRef
5.
go back to reference Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 1993,13(4):322–338.PubMedCrossRef Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 1993,13(4):322–338.PubMedCrossRef
6.
go back to reference Caro JJ: Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005,23(4):323–332. 10.2165/00019053-200523040-00003PubMedCrossRef Caro JJ: Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005,23(4):323–332. 10.2165/00019053-200523040-00003PubMedCrossRef
7.
go back to reference Keller MB, Boland RJ: Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998,44(5):348–360. 10.1016/S0006-3223(98)00110-3PubMedCrossRef Keller MB, Boland RJ: Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998,44(5):348–360. 10.1016/S0006-3223(98)00110-3PubMedCrossRef
8.
go back to reference Akerblad AC, Bengtsson F, von Knorring L, Ekselius L: Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol 2006,21(2):117–124. 10.1097/01.yic.0000199452.16682.b8PubMedCrossRef Akerblad AC, Bengtsson F, von Knorring L, Ekselius L: Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol 2006,21(2):117–124. 10.1097/01.yic.0000199452.16682.b8PubMedCrossRef
9.
go back to reference Keller MB: The long-term treatment of depression. J Clin Psychiatry 1999,60(Suppl 17):41–45.PubMed Keller MB: The long-term treatment of depression. J Clin Psychiatry 1999,60(Suppl 17):41–45.PubMed
10.
go back to reference Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al.: Multiple recurrences of major depressive disorder. Am J Psychiatry 2000,157(2):229–233. 10.1176/appi.ajp.157.2.229PubMedCrossRef Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, et al.: Multiple recurrences of major depressive disorder. Am J Psychiatry 2000,157(2):229–233. 10.1176/appi.ajp.157.2.229PubMedCrossRef
11.
go back to reference Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RM: The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 1986,143(1):24–28.PubMedCrossRef Keller MB, Lavori PW, Rice J, Coryell W, Hirschfeld RM: The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 1986,143(1):24–28.PubMedCrossRef
12.
go back to reference Olfson M, Marcus SC, Tedeschi M, Wan GJ: Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006,163(1):101–108. 10.1176/appi.ajp.163.1.101PubMedCrossRef Olfson M, Marcus SC, Tedeschi M, Wan GJ: Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006,163(1):101–108. 10.1176/appi.ajp.163.1.101PubMedCrossRef
13.
go back to reference Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K: The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998,55(12):1128–1132. 10.1001/archpsyc.55.12.1128PubMedCrossRef Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K: The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998,55(12):1128–1132. 10.1001/archpsyc.55.12.1128PubMedCrossRef
14.
go back to reference Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, et al.: Gender differences in depression: findings from the STAR*D study. J Affect Disord 2005,87(2–3):141–150. 10.1016/j.jad.2004.09.008PubMedCrossRef Marcus SM, Young EA, Kerber KB, Kornstein S, Farabaugh AH, Mitchell J, et al.: Gender differences in depression: findings from the STAR*D study. J Affect Disord 2005,87(2–3):141–150. 10.1016/j.jad.2004.09.008PubMedCrossRef
15.
16.
go back to reference NICE guidance on Depression: management of depression in primary and secondary care 2004. NICE guidance on Depression: management of depression in primary and secondary care 2004.
17.
go back to reference Kennedy SH, Lam RW, Cohen NL, Ravindran AV: Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001,46(Suppl 1):38S-58S.PubMed Kennedy SH, Lam RW, Cohen NL, Ravindran AV: Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001,46(Suppl 1):38S-58S.PubMed
18.
go back to reference Dardennes R, Lafuma A, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G: Economic Assessment of a Maintenance Treatment Strategy in Prevention of Recurrent Depressive Disorder. Value in Health 2000,3(1):40–47. 10.1046/j.1524-4733.2000.31005.xPubMedCrossRef Dardennes R, Lafuma A, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G: Economic Assessment of a Maintenance Treatment Strategy in Prevention of Recurrent Depressive Disorder. Value in Health 2000,3(1):40–47. 10.1046/j.1524-4733.2000.31005.xPubMedCrossRef
19.
go back to reference Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine S, et al.: Cost-Utility of Maintenance Treatment of Recurrent Depression with Sertraline Versus Episodic Treatment with Dothiepin. Pharmacoeconomics 1994,5(3):249–264.PubMedCrossRef Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine S, et al.: Cost-Utility of Maintenance Treatment of Recurrent Depression with Sertraline Versus Episodic Treatment with Dothiepin. Pharmacoeconomics 1994,5(3):249–264.PubMedCrossRef
20.
go back to reference Kamlet MS, Paul N, Greenhouse J, Kupfer D, Frank E, Wade M: Cost-Utility Analysis of Maintenance Treatment for Recurrent Depression. Controlled Clinical Trials 1995,16(1):17–40. 10.1016/0197-2456(94)00020-4PubMedCrossRef Kamlet MS, Paul N, Greenhouse J, Kupfer D, Frank E, Wade M: Cost-Utility Analysis of Maintenance Treatment for Recurrent Depression. Controlled Clinical Trials 1995,16(1):17–40. 10.1016/0197-2456(94)00020-4PubMedCrossRef
21.
go back to reference Lafuma A, Dardennes R, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G: Economic assessment of maintenance treatment of recurrent depressive disorder with milnacipran versus episode treatment. Encephale-Revue de Psychiatrie Clinique Biologique et Therapeutique 1999,25(5):401–407. Lafuma A, Dardennes R, Fagnani F, Pribil C, Bisserbe JC, Berdeaux G: Economic assessment of maintenance treatment of recurrent depressive disorder with milnacipran versus episode treatment. Encephale-Revue de Psychiatrie Clinique Biologique et Therapeutique 1999,25(5):401–407.
22.
go back to reference Nuijten M, Hardens M, Souetre E: A Markov Process Analysis Comparing the Cost-Effectiveness of Maintenance Therapy with Citalopram Versus Standard Therapy in Major Depression. Pharmacoeconomics 1995,8(2):159–168.PubMedCrossRef Nuijten M, Hardens M, Souetre E: A Markov Process Analysis Comparing the Cost-Effectiveness of Maintenance Therapy with Citalopram Versus Standard Therapy in Major Depression. Pharmacoeconomics 1995,8(2):159–168.PubMedCrossRef
23.
go back to reference Nuijten M, Hadjadjeba L, Evans C, van den Berg J: Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998,14(4):433–445. 10.2165/00019053-199814040-00009PubMedCrossRef Nuijten M, Hadjadjeba L, Evans C, van den Berg J: Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998,14(4):433–445. 10.2165/00019053-199814040-00009PubMedCrossRef
24.
go back to reference Patten SB, Lee RC: Epidemiological theory, decision theory and mental health services research. Soc Psychiatry Psychiatr Epidemiol 2004,39(11):893–898. 10.1007/s00127-004-0872-zPubMedCrossRef Patten SB, Lee RC: Epidemiological theory, decision theory and mental health services research. Soc Psychiatry Psychiatr Epidemiol 2004,39(11):893–898. 10.1007/s00127-004-0872-zPubMedCrossRef
25.
go back to reference Patten SB, Lee RC: Towards a dynamic description of major depression epidemiology. Epidemiol Psichiatr Soc 2004,13(1):21–28.PubMedCrossRef Patten SB, Lee RC: Towards a dynamic description of major depression epidemiology. Epidemiol Psichiatr Soc 2004,13(1):21–28.PubMedCrossRef
26.
go back to reference Patten SB, Lee RC: Refining estimates of major depression incidence and episode duration in Canada using a Monte Carlo Markov model. Med Decis Making 2004,24(4):351–358. 10.1177/0272989X04267008PubMedCrossRef Patten SB, Lee RC: Refining estimates of major depression incidence and episode duration in Canada using a Monte Carlo Markov model. Med Decis Making 2004,24(4):351–358. 10.1177/0272989X04267008PubMedCrossRef
27.
go back to reference Patten SB: Modelling major depression epidemiology and assessing the impact of antidepressants on population health. Int Rev Psychiatry 2005,17(3):205–211. 10.1080/09540260500072242PubMedCrossRef Patten SB: Modelling major depression epidemiology and assessing the impact of antidepressants on population health. Int Rev Psychiatry 2005,17(3):205–211. 10.1080/09540260500072242PubMedCrossRef
28.
go back to reference Patten SB: Markov models of major depression for linking psychiatric epidemiology to clinical practice. Clin Pract Epidemol Ment Health 2005,1(1):2. 10.1186/1745-0179-1-2CrossRef Patten SB: Markov models of major depression for linking psychiatric epidemiology to clinical practice. Clin Pract Epidemol Ment Health 2005,1(1):2. 10.1186/1745-0179-1-2CrossRef
29.
go back to reference Patten SB, Lee RC: Describing the longitudinal course of major depression using Markov models: data integration across three national surveys. Popul Health Metr 2005, 3: 11. 10.1186/1478-7954-3-11PubMedCentralPubMedCrossRef Patten SB, Lee RC: Describing the longitudinal course of major depression using Markov models: data integration across three national surveys. Popul Health Metr 2005, 3: 11. 10.1186/1478-7954-3-11PubMedCentralPubMedCrossRef
30.
go back to reference Davies R: An assessment of models of a health system. J Oper Res Soc 1985,36(8):679–687. 10.2307/2582263PubMedCrossRef Davies R: An assessment of models of a health system. J Oper Res Soc 1985,36(8):679–687. 10.2307/2582263PubMedCrossRef
31.
go back to reference Jacobson S, Hall S, Swisher J: Discrete Event Simulation of Health Care Systems. In Delay Management in Healthcare Systems. Edited by: Hall R. Springer in Health Care Management; 2006. Jacobson S, Hall S, Swisher J: Discrete Event Simulation of Health Care Systems. In Delay Management in Healthcare Systems. Edited by: Hall R. Springer in Health Care Management; 2006.
32.
go back to reference Law A, Kelton W: Simulation Modeling and Analysis. 3rd edition. Mc Graw Hill; 2000. Law A, Kelton W: Simulation Modeling and Analysis. 3rd edition. Mc Graw Hill; 2000.
33.
go back to reference Stahl JE, Rattner D, Wiklund R, Lester J, Beinfeld M, Gazelle GS: Reorganizing the system of care surrounding laparoscopic surgery: a cost-effectiveness analysis using discrete-event simulation. Med Decis Making 2004,24(5):461–471. 10.1177/0272989X04268951PubMedCrossRef Stahl JE, Rattner D, Wiklund R, Lester J, Beinfeld M, Gazelle GS: Reorganizing the system of care surrounding laparoscopic surgery: a cost-effectiveness analysis using discrete-event simulation. Med Decis Making 2004,24(5):461–471. 10.1177/0272989X04268951PubMedCrossRef
34.
go back to reference Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P, et al.: Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003,10(3):148–156. 10.1258/096914103769011067PubMedCrossRef Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P, et al.: Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen 2003,10(3):148–156. 10.1258/096914103769011067PubMedCrossRef
35.
go back to reference Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA: Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005,8(5):549–561. 10.1111/j.1524-4733.2005.00049.xPubMedCrossRef Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA: Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005,8(5):549–561. 10.1111/j.1524-4733.2005.00049.xPubMedCrossRef
36.
go back to reference Zarkin GA, Dunlap LJ, Hicks KA, Mamo D: Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ 2005,14(11):1133–1150. 10.1002/hec.999PubMedCrossRef Zarkin GA, Dunlap LJ, Hicks KA, Mamo D: Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ 2005,14(11):1133–1150. 10.1002/hec.999PubMedCrossRef
37.
go back to reference Rauner M, Brailsford S, Flessa S: Use of discrete-event simulation to evaluate strategies for the prevention of mother-to-child transmission of HIV in developing countries. Journal of the Operational Research Society 2005, 56: 222–233. 10.1057/palgrave.jors.2601884CrossRef Rauner M, Brailsford S, Flessa S: Use of discrete-event simulation to evaluate strategies for the prevention of mother-to-child transmission of HIV in developing countries. Journal of the Operational Research Society 2005, 56: 222–233. 10.1057/palgrave.jors.2601884CrossRef
38.
go back to reference Brown J, Karnon J, Eldabi T, Paul RJ: Using modelling in a phased approach to the economic evaluation of adjuvant therapy for early breast cancer. ABC Trial Steering Committee. Crit Rev Oncol Hematol 1999,32(2):95–103.PubMedCrossRef Brown J, Karnon J, Eldabi T, Paul RJ: Using modelling in a phased approach to the economic evaluation of adjuvant therapy for early breast cancer. ABC Trial Steering Committee. Crit Rev Oncol Hematol 1999,32(2):95–103.PubMedCrossRef
39.
go back to reference Karnon J, Brown J: Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci 1998,1(2):133–140. 10.1023/A:1019090401655PubMedCrossRef Karnon J, Brown J: Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci 1998,1(2):133–140. 10.1023/A:1019090401655PubMedCrossRef
40.
go back to reference Ratcliffe J, Young T, Buxton M, Eldabi T, Paul R, Burroughs A, et al.: A simulation modelling approach to evaluating alternative policies for the management of the waiting list for liver transplantation. Health Care Manag Sci 2001,4(2):117–124. 10.1023/A:1011405610919PubMedCrossRef Ratcliffe J, Young T, Buxton M, Eldabi T, Paul R, Burroughs A, et al.: A simulation modelling approach to evaluating alternative policies for the management of the waiting list for liver transplantation. Health Care Manag Sci 2001,4(2):117–124. 10.1023/A:1011405610919PubMedCrossRef
41.
go back to reference Barton P, Bryan S, Robinson S: Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004,9(2):110–118. 10.1258/135581904322987535PubMedCrossRef Barton P, Bryan S, Robinson S: Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004,9(2):110–118. 10.1258/135581904322987535PubMedCrossRef
42.
go back to reference Brennan A, Chick SE, Davies R: A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006, 15: 1295–1310. 10.1002/hec.1148PubMedCrossRef Brennan A, Chick SE, Davies R: A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006, 15: 1295–1310. 10.1002/hec.1148PubMedCrossRef
43.
go back to reference Glynn P: On the role of generalized semi-Markov processes in simulation output analysis. Winter Simulation Conference – Proceedings of the 15th conference on Winter simulation 1983, 1: 39–44. Glynn P: On the role of generalized semi-Markov processes in simulation output analysis. Winter Simulation Conference – Proceedings of the 15th conference on Winter simulation 1983, 1: 39–44.
44.
go back to reference Glynn P: A GSMP formalism for discrete event systems. Proceedings of the IEEE 1989,77(1):14–23. 10.1109/5.21067CrossRef Glynn P: A GSMP formalism for discrete event systems. Proceedings of the IEEE 1989,77(1):14–23. 10.1109/5.21067CrossRef
45.
go back to reference Eddy DM: Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance. Pharmacoeconomics 2006,24(9):837–844. 10.2165/00019053-200624090-00002PubMedCrossRef Eddy DM: Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance. Pharmacoeconomics 2006,24(9):837–844. 10.2165/00019053-200624090-00002PubMedCrossRef
46.
go back to reference Barton P, Jobanputra P, Wilson J, Bryan S, Burls A: The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004,8(11):1–104.CrossRef Barton P, Jobanputra P, Wilson J, Bryan S, Burls A: The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004,8(11):1–104.CrossRef
47.
go back to reference Sargent R: Validation and verification of simulation models. Proceedings of the 2004 Winter Simulation Conference 2004. Sargent R: Validation and verification of simulation models. Proceedings of the 2004 Winter Simulation Conference 2004.
48.
go back to reference Shechter S, Schaefer A, Braithwaite R, Roberts M: Increasing the Efficiency of Monte Carlo Cohort Simulationswith Variance Reduction Techniques. Technical note. Medical Decision Making 2006. Shechter S, Schaefer A, Braithwaite R, Roberts M: Increasing the Efficiency of Monte Carlo Cohort Simulationswith Variance Reduction Techniques. Technical note. Medical Decision Making 2006.
49.
go back to reference Christodoulou K, Vlahos K: Variable structure modelling of dynamic industry systems. Journal of the Operational Research Society 2000, 51: 1029–1040. 10.1057/palgrave.jors.2601007CrossRef Christodoulou K, Vlahos K: Variable structure modelling of dynamic industry systems. Journal of the Operational Research Society 2000, 51: 1029–1040. 10.1057/palgrave.jors.2601007CrossRef
50.
go back to reference Roy R, Arunachalam R: Parallel discrete event simulation algorithm for manufacturing supply chains. Journal of the Operational Research Society 2004, 55: 622–629. 10.1057/palgrave.jors.2601688CrossRef Roy R, Arunachalam R: Parallel discrete event simulation algorithm for manufacturing supply chains. Journal of the Operational Research Society 2004, 55: 622–629. 10.1057/palgrave.jors.2601688CrossRef
51.
go back to reference Davis RM: An interactive simulation in the Health Service. Journal of the Operational Research Society 1985,36(7):597–606. 10.2307/2582477CrossRef Davis RM: An interactive simulation in the Health Service. Journal of the Operational Research Society 1985,36(7):597–606. 10.2307/2582477CrossRef
Metadata
Title
Can discrete event simulation be of use in modelling major depression?
Authors
Agathe Le Lay
Nicolas Despiegel
Clément François
Gérard Duru
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2006
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/1478-7547-4-19

Other articles of this Issue 1/2006

Cost Effectiveness and Resource Allocation 1/2006 Go to the issue